Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone versus placebo to prevent saphenous vein graft atherosclerosis progression after CABG in diabetic patients
2005-000013-36Phase 3Active
- Sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atherosclerosis of coronary artery bypass graft and type 2 diabetes mellitus (T2DM) comparing Rosiglitazone with Placebo (2 arms). Primary endpoint: Change in plaque volume in saphenous vein graft segment. Started Nov 2005; status: active.
02
Drugs
rosiglitazone
03
Conditions
Atherosclerosis of coronary artery bypass grafttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-000013-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000013-36.